"Efesovir (FS-1) for COVID-19, Phase 2"

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

November 30, 2026

Conditions
Covid19
Interventions
DRUG

Efesovir

Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.

Trial Locations (1)

071407

Semey Medical University, Semey

All Listed Sponsors
lead

Scientific Center for Anti-infectious Drugs, Kazakhstan

INDUSTRY